Day: June 22, 2020

Inhibition significative du mimétisme vasculogénique observée avec le TH1902 et le TH1904Activité anticancéreuse accrue de la curcumine conjuguée avec un peptide exclusifLa technologie SORT1+ élargit significativement la fenêtre thérapeutique des traitements cytotoxiques traditionnels du cancerMONTRÉAL, 22 juin 2020 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), une société biopharmaceutique commerciale, a le plaisir d’annoncer que de nouvelles données sur ses conjugués peptide-médicament (PCM) expérimentaux ciblant la sortiline (SORT1) feront l’objet de trois affiches qui seront présentées lors du congrès annuel virtuel II de l’American Association for Cancer Research (AACR).« Nous croyons que la technologie SORT1+ est un des progrès les plus prometteurs dans le traitement du cancer depuis...

REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced dosing of the first patient in a multicenter Phase 1 clinical trial evaluating the combination of RMC-4630 (SAR442720), the company’s investigational SHP2 inhibitor, and pembrolizumab (Keytruda®), an anti-PD-1 antibody. The trial, which is being sponsored and conducted by the company’s collaboration partner Sanofi, is an open-label, safety, preliminary efficacy and pharmacokinetics study in participants with advanced malignancies. This will include patients with non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy, and patients with colorectal cancer who have progressed...

PV-10 treatment leads to STING dimerizationResearchers identify potential association of heat shock proteins with STING in PV-10-treated modelsKNOXVILLE, TN, June 22, 2020 (GLOBE NEWSWIRE) — Provectus (OTCQB: PVCT) today is pleased to announce that data from ongoing preclinical study of investigational autolytic cancer immunotherapy PV-10 (rose bengal disodium) is being presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II, held online June 22-24, 2020. This PV-10 research has been led by Aru Narendran, MD, PhD and his team of researchers at the University of Calgary in Alberta, Canada (UCalgary).Dr. Narendran and his colleagues studied the effects of PV-10 treatment on primary cells and cell lines derived from pediatric leukemia patients. UCalgary showed that PV-10 treatment led to STING...

COLUMBIA, Md., June 22, 2020 (GLOBE NEWSWIRE) — Rekor Systems, Inc. (NASDAQ:REKR) (“Rekor”) (“the Company”), a Maryland-based company providing real-time roadway intelligence through AI-driven decisions, today announced that the U.S. Department of Defense (DOD) has authorized $160,000 for the purchase of the Company’s vehicle recognition software. These licenses will allow Rekor’s AI-powered vehicle recognition software to be deployed quickly to existing cameras to support national security efforts.“When it comes to national security, the Department of Defense has exacting standards,” said Robert A. Berman, President and CEO, Rekor. “Knowing the wide range of solutions they have at their disposal, we are pleased they are continuing to expand their use of Rekor’s best-in-class, machine learning and artificial intelligence-based...

TROY, Mich., June 22, 2020 (GLOBE NEWSWIRE) — Kelly, a global leader in providing workforce solutions, today announced the appointment of the company’s five specialty business leaders and a chief administrative officer.Earlier this year, Peter Quigley, Kelly president and chief executive officer, unveiled the company’s strategy to accelerate growth as a specialty talent solutions provider. Under this strategy, the company will manage its business through five specialized business segments, each with a president dedicated to driving innovation, execution, and growth within their specialty.“The leadership team we’re announcing today sets Kelly on a clear path to becoming a specialty talent solutions company that accelerates profitable growth, is a career partner for key talent, and delivers differentiated value to our clients,” said...

NEW YORK and TORONTO, June 22, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), an emerging leader in augmented reality for eCommerce, AR learning applications, and virtual events is pleased to announce it has signed a one year contract to provide its InfernoAR Virtual Events video conferencing platform services to Real Asset Media. The initial contract value is for $135,000 with the potential for substantial additional revenue as augmented reality use cases emerge.Real Asset Media is a leading pan-European event provider, creating forums in the major centers of Europe to link local market investment expertise with pools of capital in the UK, Germany, France, Holland, Scandinavia and beyond into the US, North America, M/E and Asia. Real Asset Media will launch REALX.global, the virtual...

Update Provided Phase I Study of MT-5111 in HER2-positive CancersConference Call and Webcast to Discuss AACR Posters on June 25th at 10:30am Eastern TimeAUSTIN, Texas, June 22, 2020 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), announced that four poster presentations featuring pre-clinical data on its pipeline programs are being presented at the American Association of Cancer Research (AACR) Virtual Annual Meeting 2020, being held June 22-24, 2020. Copies of the posters presented at AACR can be found in the Presentations section of Molecular Templates’ website at http://ir.mtem.com/events-and-presentations/presentations....

RICHMOND HILL, Ontario, June 22, 2020 (GLOBE NEWSWIRE) — Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it will be presenting at Proactive One2One Virtual Investor Forum on June 23, 2020.Dr. Heman Chao, Chief Executive Officer of Helix is scheduled to present on Tuesday, June 23rd at approximately 1:20pm Eastern Time. The presentation will be webcast live on the conference event platform. You can access the invitation and register to the Investor Forum with the following link:https://www.proactiveinvestors.co.uk/companies/news/922066/biotech-companies-to-dominate-at-proactive-one2one-virtual-investor-forum-on-june-23-922066.htmlAbout Proactive InvestorsWith offices in the US and in Canada,...

Interim data demonstrate that HB‑101 is well toleratedHB-101 elicits T cell and B cell responses in the target populationNEW YORK and VIENNA, Austria, June 22, 2020 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced positive interim results on its prophylactic Cytomegalovirus (CMV) vaccine candidate HB‑101. HB‑101 is being investigated in a double-blind Phase 2 clinical trial (NCT03629080) to assess safety, immunogenicity and efficacy in patients receiving a kidney transplant from a live donor. HOOKIPA reported interim data on the trial’s primary endpoints, safety and B cell and T cell immunogenicity.Trial participants were blinded and randomized 2:1 to receive...